Implementation of RTS, S/AS01 malaria vaccine - The need for further evidence

New England Journal of Medicine

Volumn 374, Issue 26, 2016, Pages 2596-2597

  Clemens, John ^a   Moorthy, Vasee ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE; RECOMBINANT VACCINE;

AFRICA SOUTH OF THE SAHARA; AGE; CHILD HEALTH CARE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DISEASE TRANSMISSION; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MALARIA CONTROL; MALARIA FALCIPARUM; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WORLD HEALTH ORGANIZATION; FEMALE; IMMUNOLOGY; MALARIA, FALCIPARUM; MALE;

FEMALE; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; PLASMODIUM FALCIPARUM; VACCINES, SYNTHETIC;

EID: 84976498428     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1606007     Document Type: Editorial

References (9)

1. WHO. Malaria vaccine: WHO position paper - January 2016. Wkly Epidemiol Rec 2016; 91: 33-51.
2. Regules JA, Cummings JF, Ockenhouse CF. The RTS, S vaccine candidate for malaria. Expert Rev Vaccines 2011; 10: 589-99.
3. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386: 31-45.
4. Penny MA, Verity R, Bever CA, et al. Public health impact and cost-effectiveness of the RTS, S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet 2016; 387:367-75.
5. European Medicines Agency. First malaria vaccine receives positive scientific opinion from EMA (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2015/07/news-detail-002376.jsp?=WC0b01ac058004d5c1).
6. SAGE/MPAC evidence to recommendations table on the use of malaria vaccines. Geneva: World Health Organization, 2015 (http://www.who.int/immunization/policy/position-papers/malaria-evidence-recommendations-table.pdf).
7. Clemens J, Jodar L. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat Med 2005; 11:Suppl:S12-5.
8. Olotu A, Fegan G, Wambua J, et al. Seven-year efficacy of RTS, S/AS01 malaria vaccine among young African children. N Engl J Med 2016; 374: 2519-29.
9. Olotu A, Fegan G, Wambua J, et al. Four-year efficacy of RTS, S/AS01E and its interaction with malaria exposure. N Engl J Med 2013; 368:1111-20.